Will Ekso Bionics Holdings Inc stock go up?

According to Danelfin AI, Ekso Bionics Holdings Inc has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (33.23%) is -17.59% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Ekso Bionics Holdings Inc stock?

The Ekso Bionics Holdings Inc target price is $71.5 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Ekso Bionics Holdings Inc stock right now?

Ekso Bionics Holdings Inc has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (33.23%) is -17.59% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis.

Is Ekso Bionics Holdings Inc undervalued right now?

Based on analysts, the average price target upside for Ekso Bionics Holdings Inc is +304.86% (1Y). According to Danelfin AI, Ekso Bionics Holdings Inc has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Ekso Bionics Holdings Inc stock over the past 12 months?

The Ekso Bionics Holdings Inc stock price range over the past 12 months has been - - -.

What is going on with Ekso Bionics Holdings Inc stock in the last 3 months?

The Ekso Bionics Holdings Inc stock performance in the last quarter has been -.

Does Ekso Bionics Holdings Inc offer dividend payments?

No, Ekso Bionics Holdings Inc does not currently pay dividends.

What is the current market capitalization of Ekso Bionics Holdings Inc?

Ekso Bionics Holdings Inc's market cap is $2.52B, as of 2026-07-02 08:00.

When is the next CHRN earnings report date?

CHRN will publish its next earnings report on 2026-02-19.

Ekso Bionics Holdings Inc (CHRN) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CHRN AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Ekso Bionics Holdings Inc today receives an AI Score of 1/10, which translates to a Strong Sell rating. The stock has a 34% probability of outperforming the market in the next 3 months, which is 17% lower than the average probability of any stock (51%). The top positive contributor is the Earnings Countdown signal, which adds +0.56% to the probability, despite being in the bottom 10% (days since last earnings). However, all other impactful signals detract from the probability. The strongest detractors include the Industry (Health Care Equipment & Supplies) reducing probability by -2.33%, Analyst Mean Price Target Upside in the bottom 10% reducing by -1.86%, and Technicals Impact (Long Tail) reducing by -1.65%. Additional negative impacts come from Maximum Volatility (top 10%) at -1.40%, ATR (14d Volatility) (top 20%) at -1.39%, and Fear & Greed Index at -1.16%. Fundamental weaknesses such as Basic EPS (bottom 10%), Institutional Ownership (bottom 10%), Beginning Cash (bottom 10%), Operating Profit Margin (bottom 10%), and Cash per Share (bottom 10%) each reduce probability by -1.16%, -1.12%, -1.02%, -0.75%, and -0.46% respectively. Volatility metrics like Minimum Volatility (top 10%) and Normalized ATR (top 10%) also detract by -0.62% and -0.56%. Tangible Shareholders' Equity (bottom 30%) and Net PP&E (bottom 20%) further reduce probability by -0.51% and -0.44%. Notable data points include the stock's extremely low analyst price target upside (mean target price is 45% below current price), placing it in the bottom 10% of all stocks. The company has negative earnings per share (-$1.93), a deeply negative operating profit margin (-262.4%), and very low cash reserves ($1.17 million beginning cash, $0.03 cash per share), all in the bottom 10%. Volatility is extremely high, with maximum and minimum volatility both in the top 10%, and ATR in the top 20%, indicating large price swings. The Fear & Greed Index reading of 31 suggests fearful market sentiment. The only positive signal is the Earnings Countdown, which is in the bottom 10% (127 days since last earnings), but its impact is minimal. Overall, the stock faces severe headwinds from poor fundamentals, high volatility, negative analyst sentiment, and a challenging industry context, resulting in a very low probability of outperforming the market and a Strong Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Sentiment-6.27%
How analysts and the market view the stock
Volatility-4.28%
How much the stock price tends to fluctuate
Valuation-1.95%
How the stock is priced relative to its fundamentals
Momentum-1.86%
Direction and strength of recent price movements
Growth-1.16%
Expected pace of revenue and earnings expansion
Size & Liquidity-1.02%
Company size and trading liquidity
Profitability-0.75%
Profitability and operating efficiency metrics
Financial Strength-0.31%
Balance sheet strength and financial resilience

CHRN probability advantage of beating the market (3M):

-17.59%

AI Score

Strong Sell

Ekso Bionics Holdings Inc (CHRN) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -17.59% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of CHRN (33.23%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
CHRN probability advantage of beating the market (3M)-17.59%
CHRN probability of beating the market (3M)33.23%

CHRN probability advantage of beating the market (3M): -17.59%

The AI-powered overall analysis of Ekso Bionics Holdings Inc (CHRN) is based on the 22 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CHRN:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-2.33%
Sentiment	Analyst Mean Price Target Upside	-0.45%	N/A	-1.86%
Technical	Technicals Impact (Long Tail)	-	N/A	-1.65%
Technical	Maximum Volatility	17.11%		-1.40%
Technical	ATR (14d Volatility)	2.99		-1.39%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.16%
Fundamental	Basic EPS Consolidated	-1.93	N/A	-1.16%
Sentiment	Institutional Ownership	0.63%	N/A	-1.12%
Fundamental	Beginning Cash (Millions)	1.17	N/A	-1.02%
Fundamental	Operating Profit Margin	-262.40%	N/A	-0.75%
Technical	Upgrade to unlock			-0.62%
Technical	Upgrade to unlock			-0.56%
Sentiment	Upgrade to unlock			+0.56%
Fundamental	Upgrade to unlock			-0.51%
Fundamental	Upgrade to unlock			-0.46%

Rest of Alpha Signals: -1.63%

CHRN probability advantage of beating the market (3M)Total:-17.59%
CHRN AI Score

Significant changes Vs previous day

CHRN Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$17.66
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

CHRN Proven Sell Signal & Price Forecast

This is the price chart for CHRN from January 1, 2026 until today. The chart indicates, in red, the 38 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CHRN Average Past Performance & Loss Rate

Three months after its 32 Sell signals since July 2026, CHRN had an average performance of xxxxx and a xxxxxxx Loss rate (negative performance).

32 Past CHRN Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				0.00%
Average Alpha				0.00%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

CHRN Frequently Asked Questions

Will Ekso Bionics Holdings Inc stock go up?
According to Danelfin AI, Ekso Bionics Holdings Inc has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (33.23%) is -17.59% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Ekso Bionics Holdings Inc stock?
Is it a good time to buy, sell, or hold Ekso Bionics Holdings Inc stock right now?
Is Ekso Bionics Holdings Inc undervalued right now?
What was the price range of Ekso Bionics Holdings Inc stock over the past 12 months?
What is going on with Ekso Bionics Holdings Inc stock in the last 3 months?
Does Ekso Bionics Holdings Inc offer dividend payments?
What is the current market capitalization of Ekso Bionics Holdings Inc?
When is the next CHRN earnings report date?

Ekso Bionics Holdings Inc Company Profile

Ekso Bionics Holdings Inc (CHRN) develops and commercializes robotic exoskeletons. These advanced wearable devices provide physical support and enhance human mobility. The company focuses on applications within the medical and industrial sectors. Its technology aims to improve rehabilitation outcomes for patients and augment worker capabilities in demanding environments.

Within the medical domain, Ekso Bionics offers specialized robotic exoskeletons for rehabilitation therapy. These medical devices assist individuals recovering from various neurological conditions and injuries. Patients with stroke, spinal cord injuries, or traumatic brain injuries utilize these systems to regain mobility. The technology supports intensive gait training and helps restore motor function. Its EksoNR system facilitates early mobilization and provides dynamic assistance during therapy sessions. This system allows therapists to guide patients through natural walking patterns, adapting to individual patient needs. It helps patients regain strength, balance, and coordination, contributing to improved functional independence and quality of life.

For industrial applications, the company provides solutions designed to enhance worker safety and productivity. These industrial exoskeletons reduce physical strain and fatigue for workers performing physically demanding tasks. They support individuals engaged in repetitive or strenuous activities across various industries, including manufacturing and construction. The devices help prevent musculoskeletal injuries and improve overall ergonomic conditions in the workplace. Its EksoVest system specifically supports workers performing overhead or chest-level tasks. This wearable technology augments upper body strength and endurance. It allows workers to perform demanding tasks with less effort and greater comfort over extended periods. It contributes to a safer and more efficient work environment.

Ekso Bionics serves a diverse customer base, including healthcare providers, rehabilitation centers, and industrial enterprises. The company reaches these customers through a combination of direct sales efforts and a global network of distribution partners. Its offerings include the sale of advanced exoskeleton systems, along with associated services, maintenance, and software. Revenue primarily derives from product sales, service contracts, and recurring software subscriptions, distributed through direct and channel sales to customers worldwide.

Sector:Health Care
Country:United States
Industry:
Address:101 Glacier Point, Suite A, San Rafael California
Employees:50
Website:eksobionics.com

Pros

High switching costs in rehabilitation device integration

Proprietary technology and patent portfolio protection

Regulatory approval barrier for medical devices

Demand growth from aging global demographics

Diversification into industrial exoskeleton applications

Cons

Substantial capital expenditure for research and development

Reimbursement policy uncertainty for medical devices

Niche market penetration for exoskeleton technology

Technological disruption risk from alternative therapies

Potential customer concentration in healthcare systems

Company	AI Score	Compare
LFWDLifeward Ltd
ZBHZimmer Biomet Holdings Inc
ENOVEnovis Corp
HNGEHinge Health Inc
MYOMyomo Inc

Company	AI Score	Compare
LFWDLifeward Ltd
ZBHZimmer Biomet Holdings Inc
ENOVEnovis Corp
HNGEHinge Health Inc
MYOMyomo Inc

CHRN Stock AI Analysis High Risk